Read about CCNet and our products in these publications:
Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and pro-mutagens in vitro
Boehme K, Dietz Y, Hewitt P, Mueller SO
Toxicol. Sci. 2011
Toxwiz was used here to help study toxicogenomics data from rat livers treated with pro-mutagentic compounds.
Read more
Data Mining in Drug Development and Translational Medicine Overview
Mucke H
Insight Pharma Reports 2011
Read more
Specific pages
Hepatic transcriptome and proteome responses against diethyl maleate-induced glutathione depletion in the rat
Yamauchi S, Kiyosawa N, Ando Y, Watanabe K, Niino N, Ito K, Yamoto T, Manabe S, Sanbuissho A.
Arch Toxicol. 2010
Toxwiz was used here to probe chemical to gene relations in a microarray set from diethyl maleate treated livers.
Read more
Unraveling Mechanisms of Toxicity with the Power of Pathways: ToxWiz as an Illustrative Example
Kuehnel MP, Cosovic B, Medic G, Russell RB, Apic G
Pathway Analysis for Drug Discovery
Read more
Current Limitations and Future Prospects for Applying Systems Biology in Drug Discovery and the Clinic
Apic G, Russell RB.
Bioworld Europe, 3, 13-15, 2007
"Most Systems Biology scenarios advocate the use of data recently delivered by post-genomic technologies (microarrays, proteomics, etc.), but it is also important to consider data generated during the past decades of molecular biology, biochemistry, pharmaceutical and clinical research. The technical challenge is to somehow combine data sources as diverse as the scientific literature, DNA microarrays, high-throughput screens, toxicology studies or clinical trials to make usable predictive systems."
Read more
CCNet features in Genetic Engineering News
Omics: Toxicogenomics Enhances Drug Discovery
Working Toward Improving Hazard Identification and Risk Assessment
by Kathy Liszewski
"...Harnessing the power of computational modeling of biological pathways can help decipher molecular mechanisms of toxicity, according to Gordana Apic, Ph.D., CEO, Cambridge Cell Networks (www.camcellnet.com). "One of the biggest challenges in drug discovery today is understanding the molecular mechanisms of drug actions and mechanistic toxicity. Our company provides a series of products for elucidating mechanisms of toxicity. We use a multidisciplinary approach integrating bioinformatics, genomics and proteomics, chemistry, text mining, and mathematics." The company provides databases and core softwares. For example, they offer a manually curated database of more than 25,000 chemical structures..."
Read more
Illuminating drug discovery with biological pathways
Apic G, Ignjatovic T, Boyer S, Russell RB.
FEBS Lett. 2005 Mar 21;579(8):1872-7.
"...One of the biggest challenges in drug discovery today is the high attrition rate: many promising candidates prove ineffective or toxic owing to a poor understanding of the molecular mechanisms of biological systems they target. A "systems" approach can help identify pathways related to a disease and can suggest secondary effects of drugs that might cause these problems and thus ultimately improve the drug discovery pipeline..."
Read more
|
|
CCNet's tools proved to be very effective in validating our candidate biomarkers. Their process of browsing the literature to find mechanisms of action was almost ten times faster than our usual way or searching.
Senior Scientist, Diagnostics Company
|
|
Case Studies